2016N290015_04 CONFIDENTIA L
GlaxoSmi thKline group of companies 206246
1TITLE PA GE
Protocol Title: An Open-label, Dose -escalation Study  to Evaluate the Safety , 
Tolerability , Pharmacokinetics and Pharmacody namicsof Single Dosesof GSK2586881 
in Participants with Pulmonary  Arterial Hypertension
Protocol Number : 206246 / Amendme nt 4
Short Title : Studyto Evaluate the Safety ,Pharmacokinetics and Pharmacody namics of 
GSK2586881 in Participants with Pulmon ary Arterial Hypertension
Compound Number: GSK2586881
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & De velopment Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Medical Monitor Name and Contact Information can be found in the Study 
Reference Manual
Regulatory Agency Identifying Number(s): EudraCT 2017-000212-41, IND132281
Approval Date: 10-JUL-2018
Copyright 2018 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2019N405280_00
 2019N405280_00
PPD
PPD
2016N290015_04 CONFIDENTIA L
206246
3PROTOCOL A MENDMENT SUMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date DNG Number
Amendment 4 10-Jul-2018 2016N290015_04
Amendment 3 01-Dec-2017 2016N290015_03
Amendment 2 07-Nov-2017 2016N290015_02
Amendment 1 03-May-2017 2016N290015_01
Original Protocol 04-Apr-2017 2016N290015_00
Amendment 4 10-JUL-2018
Overall Rationale for the Amendment:
This is a substantial amendment with changes to the inclusion and exclusion criteria 
tomore accurately reflect the patient population. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
4Section # and 
NameDescription of Change
*Bolded text indicates newly added text, and 
strikethrough indicates deleted text.Brief Rationale
6.1 Inclusion 
Criteria #3The following change was made:  
Idiopathic pulmonary arterial hypertension 
(IPAH), hereditary pulmonary arterial 
hypertension (HPAH), or PAH associated 
with collagen vascular disease , repaired 
congenital heart disease, or appetite 
suppressant use.PAH associated with repaired 
congenital heart disease was 
removed as this differs clin ically 
from other forms of PAH.
6.1 Inclusion 
Criteria #5The following change was made:
Hemodynamically stable on background 
therapy with no evidence of uncontrolled
right heart failure (historic data), as 
determined by the investigator .This change cla rifies that 
participants with uncontrolled 
right heart failure must be 
excluded . However, participants 
with controlled right heart failure 
can be included as determined 
by the investigator . 
6.1 Inclusion 
Criteria #6and 
9.4 Six-minute
walk testThe follo wing change was made:     
Six minute walk (6MW) distance, as 
performed at screening or within 6 months
prior to screening, of ≥100 meters and < 
450≤ 500 meters.Six-minute walk maximum 
distance was increased to 500
meters to allow participants to 
be incl uded that meet all other 
criteria.
6.1 Inclusion 
Criteria #10The following change was made:
Body weight <90≤ 100kg and body mass 
index (BMI) within the range 18 -3035
kg/m2(inclusive).Maximum BMI was increased to 
35 to mo re accurately reflect the 
range observed in the patient 
population .
6.2 Exclusion 
criteria # 4The following change was made:
Complex repaired and unrepaired 
congenital heart disease.This change clarifies that both 
complex repaired and 
unrepaired congenital heart 
disease will be excluded from 
the study .
6.2 Exclusion 
criteria #9The following change was made:
Estimated glomerular -filtration -rate(eGFR) 
< 6045 mL/min/1.73m2.eGFR rate was reduced to 
45ml/min/1.73m2to more 
accurately reflect the range 
observed in the patient 
popu lation.
12.2 Appendix 2: 
Clinical 
Laboratory 
TestsThe following change was made:
Activated Prothrombin time (PT)
aPTT Q2 confirmed the assay they 
use is activated prothrombin 
time (aPTT) 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
5Section # and 
NameDescription of Change
*Bolded text indicates newly added text, and 
strikethrough indicates deleted text.Brief Rationale
12.2 Appendix 2: 
Clinical 
Laboratory 
TestsThe following change was made:
Local laboratory results are only required 
in the event that the central laboratory 
results are not available in time for either 
study treatment administration and/or 
response evaluation. If a local sample is 
required, it is important that the s ample for 
central analysis is obtained at the same 
time. Additionally, if the local laboratory 
results are used to make either a study 
treatment decision or response evaluation, 
the results must be entered into the CRF.This change allows sites to use 
local labs , if necessary;
however , itensures samples are 
always collected and analysed 
centrally. 
12.5 Appendix 5: 
Contraceptive 
Guidance and 
Collection of 
Pregnancy 
InformationPregnancy testing, with a high sensitivity 
test will be performed using the t est kit 
provided by the central laboratory /and 
approved by the sponsor and in 
accordance with instructions provided in its 
package insert.This change gives flexibility for 
sites to use local labs for 
pregnancy testing.  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
6TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.SYNOPSIS ............................................................................................................... 8
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 11
3.INTRODUCTION .................................................................................................... 17
3.1. Study Rationale .......................................................................................... 18
3.2. Background ................................................................................................ 18
3.3. Benefit/Risk Assessment ............................................................................ 19
3.3.1. Risk Assessment ......................................................................... 20
3.3.2. Benefit Assessment ..................................................................... 23
3.3.3. Overall Benefit:Risk Conclusion ................................................... 23
4.OBJECTIVES AND ENDPO INTS ........................................................................... 23
5.STUDY DESIGN .................................................................................................... 24
5.1. Overall Design ............................................................................................ 24
5.2. Number of Participants ............................................................................... 24
5.3. Participant and Study Completion ............................................................... 25
5.4. Scientific Rationale for Study Design .......................................................... 25
5.5. Dose Justification ........................................................................................ 25
6.STUDY POPULATION ........................................................................................... 26
6.1. Inclusion Criteria ......................................................................................... 26
6.2. Exclusion Criteria ........................................................................................ 27
6.3. Lifestyle Restrictio ns................................................................................... 29
6.3.1. Caffeine, Alcohol, and Tobacco ................................................... 29
6.3.2. Activity ......................................................................................... 29
6.3.3. Contraception Requirements ....................................................... 29
6.4. Screen Failures ........................................................................................... 29
7.TREATMENTS ....................................................................................................... 30
7.1. Treatments Administered ............................................................................ 30
7.2. Dose Modification ....................................................................................... 30
7.3. Method of Treatment Assignment ............................................................... 31
7.4. Blinding ....................................................................................................... 31
7.5. Preparation/Handling/Storage/Accountability .............................................. 31
7.6. Treatment Compliance................................................................................ 32
7.7. Concomitant Therapy .................................................................................. 32
7.8. Treatm ent after the End of the Study .......................................................... 33
8.DISCONTINUATION CRIT ERIA ............................................................................. 33
8.1. Liver Chemistry Monitoring ......................................................................... 33
8.2. QTc Monitoring Criteria ............................................................................... 33
8.3. Withdrawal from the Study .......................................................................... 34
8.4. Lost to Follow Up ........................................................................................ 34
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 35 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
79.1. Pharmacodynamics .................................................................................... 35
9.1.1. Hemodynam ics............................................................................ 35
9.2. Adverse Events ........................................................................................... 36
9.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 36
9.2.2. Method of Detecting AEs and SAEs ............................................. 36
9.2.3. Follow -up of AEs and SAEs ......................................................... 37
9.2.4. Regulatory Reporting Requirements for SAEs ............................. 37
9.2.5. Cardiovascular and Death Events ................................................ 37
9.2.6. Pregnancy ................................................................................... 38
9.3. Treatment of Overdose ............................................................................... 38
9.4. Six-Minute W alk Test .................................................................................. 38
9.5. Safety Assessments ................................................................................... 38
9.5.1. Physical Examinations ................................................................ .39
9.5.2. Vital Signs .................................................................................... 39
9.5.3. Pulse Oximetry ............................................................................ 39
9.5.4. Electrocardiograms ...................................................................... 39
9.5.5. Telemetry ..................................................................................... 39
9.5.6. Clinical Safety Laborator y Assessments ...................................... 39
9.6. Pharmacokinetics ....................................................................................... 40
9.7. Immunogenicity Assessments ..................................................................... 41
9.8. Biomarkers ................................................................................................ .41
9.9. Genetics ..................................................................................................... 41
10.STATISTICAL CONSIDER ATIONS ........................................................................ 42
10.1. Sample Size Determination ........................................................................ 42
10.2. Populations for Analyses ............................................................................ 42
10.3. Statistical Analyses ..................................................................................... 42
10.3.1. Pharmacodynamic and Safety Analyses ...................................... 43
10.3.2. Pharmacokinetic and Pharmacokinetic -Pharmacodynamic 
Analyses ...................................................................................... 43
10.3.3. Interim Analyses .......................................................................... 44
11.REFERENCES ....................................................................................................... 45
12.APPENDICES ........................................................................................................ 47
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 47
12.2. Appendix 2: Clinical Laboratory Tests ......................................................... 50
12.3. Appendix 3: Study Governance Considerations .......................................... 52
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 56
12.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 61
12.6. Appendix 6: Genetics .................................................................................. 64
12.7. Appendix 7: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 65
12.8. Appendix 8: P rotocol Amendment History ................................................... 68 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
81. SYNOPSIS
Protocol Title: An Open-label, Dose -escalation Study  to Evaluate the Safety , 
Tolerability , Pharmacokinetics and Pharmacody namics of S ingle Doses of GSK2586881 
in Participants with Pulmon ary Arterial Hypertension
Short Title: Studyto Evaluate the Safety , Pharmacokinetics and Pharmacody namics of 
GSK2586881 in Participants with Pulmon ary Arterial Hypertension
Rationale:
GSK2586881 is a purified intravenous (IV)formulation of soluble recomb inant human 
Angiotensin Converting Enzy me (rhACE2)that is being investigated as a potential 
treatment for Pulmonary  Arterial Hy pertension (PAH).
Angiotensin converting enzy me type 2 (ACE2)is a type I, membrane -bound 
carboxypeptidase that inactivates Angi otensinII(AngII)by cleaving it to produce 
Ang(1-7).  Ang II is a key effector peptide of the Renin -Angiotensin- System (RAS) that 
can exert deleterious effects on the pulmonary  vasculature resulting in vasoconstriction, 
proliferation and inflammation, a ll of which contribute to PAH development. Conversel y
Ang(1-7) has shown vasodilatory , anti-proliferative and anti -inflammatory properties b y 
signalling through the Mas receptor andrecombinant ACE2 has proven effective in 
blocking or treating established PAHin several rodent models .
ACE2hydrolyses a number of other biological peptides, including converting A ngI to 
Ang(1-9) and removing the C -terminal residue from the bradykinin metabolites [des-
Arg9]-bradykinin and l ys[des-Arg9]-bradykinin . 
GSK2586881 has been tested in healthy  subjects and mechanically  ventilated patients 
with Acute Respiratory  Distress Sy ndrome (ARDS)and has been shown to be well 
tolerated with the rapid modulation of R AS peptide s.This will be the first 
GlaxoSmithKline (GSK)study to test the safety  and preliminary  effects on pulmonary  
hemodynamics of GSK2586881 in participants with PAH.
A detailed description of the biology , pharmacology , efficacy, and safet y of 
GSK2586881 is provided in the Investigator’s Brochure (IB).
Objectives and Endpoints :
Objectives Endpoints
Primary
 To evaluate changes in the pulmonary 
hemodynamics after single IV doses of 
GSK2586881 administered to participants 
with PAH receiving background PAH 
therapy. Change from baseline in pulmonary 
vascular resista nce (PVR) , cardiac output 
(CO) and mean pulmonary artery pressure
(mPAP) , as data permit 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
9Objectives Endpoints
Secondary
 To evaluate the safety and tolerability of 
single IV doses of GSK2586881 
administered to participants with PAH 
receiving background PAH therapy. Adverse events (AE), clinical laboratory 
values, vital signs, electrocardiogram 
(ECG), pulse oximetry and 
immunogenicity.
 To evaluate the effect of single IV doses of 
GSK2586881 on RAS peptide responses 
in participants with PAH receiving 
background PAH therapy. Change from baseline of pulmonary wedge 
and systemic RAS peptides (e.g. Ang II, 
Ang(1 -7), Ang(1 -5),and AngII/Ang(1 -7) 
ratio).
 To evaluate the effect on biomarkers of 
disease activity after single IV doses of 
GSK2586881 administered to participants 
with PAH receiving background PA H 
therapy.
 To evaluate the pharmacokinetics (PK) of 
GSK2586881 after single IVdoses of 
GSK2586881 in participants with PAH 
receiving background PAH therapy. Change from baseline in NT pro -BNP, NO 
and cardiac troponin I.
 Plasma con centrations of GSK2586881 
and derived PK parameters.
Overall Design:
This is a Phase IIa ,open-label, dose -escalation, single dose study in participants with 
PAH (as defined in the eligibility  criteria) whose sy mptoms have been clinically  stable 
for 8 weeks prior to enrolment and who have had no change in PAH- specific therapy  in 
the 12 weeks prior to enrolment.
Number of Participant s:
The total number of participants recruited will be determined through an ongoing review 
of the safet y, tolerability , PK and PD data with aminimum of 4 parti cipants recruited per
cohort. There will be 4 cohorts.  At the end of each cohort a dose esc alation meeting will 
occur and a decision will be made whether to dose escalate.  
Amaximum of 27 participants will complete do sing and critical assessments in this 
study.
If participants prematurely discontinue the stud y, additional replacement participants may 
be recruited and assigned to the same dose level at the discretion of the Sponsor in 
consultation with the investigator.
Treatment Groups and Duration:
The study  will comprise of 4 separate cohorts . Participants will be administered a single 
dose at the following planned doses: 0.1, 0.2, 0.4, or 0.8mg/kg.  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
10Dose escalation will occur after a minimum of 4 partici pants have b een dosed per cohort 
and review of safet y, tolerability , PKand hemodynamicdataup to 24h post dose has 
taken place . Dose escalation will continue up to a maximum dose of 0.8mg/kg. 
Cohort sizes may  vary with a minimum of 4 participants per cohort . Additional 
participants may  be enrolled to expand a dosing cohort to further evaluate findings at a 
given dose level.
It is anticipated that the total duration of participation in the study  will be up to a 
maximum of 59 days from screening to the last study  visit.
Study Design
0.1mg/ kg 0.8mg/ kg 0.4mg/ kg 0.2mg/ kgSingle Dose
(minimum 4 participants per cohort)
* * *
* dose esca lation meet ing (review of safety, PK and hemody namic data) 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
112. SCHEDULE OF ACTIVITI ES (SOA )
ProcedureScreening 
(up to 28 
days before 
dosing)Treatment Period Follow -
up
Day 7-
14 Follow -
upDay 
28 3 
daysNotes
Pre-
dose10h 0.08h
(5 
min)20.5h 1h 2h 4h 8h 24h
Informed consent X
Genetics consent XGenetics consent is 
Optional
Inclusion and exclusion 
criteriaXRecheck clinical 
status before 
randomization and/or 
1st dose of study 
medic ation
Demography X
Full physical examination 
including height and 
weightX
Medical history (includes 
substance usage and 
family history of premature 
CV disease)XSubstances: drugs, 
alcohol, tobacco and 
caffeine
Past and current medical 
conditions  X 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
12ProcedureScreening 
(up to 28 
days before 
dosing)Treatment Period Follow -
up
Day 7-
14 Follow -
upDay 
28 3 
daysNotes
Pre-
dose10h 0.08h
(5 
min)20.5h 1h 2h 4h 8h 24h
Serum OR urine 
pregnancy test (WOCBP 
only)X X X
FSH and estradiol test 
(postmenopausal females 
only as needed )X
Human Immunodeficiency 
Virus ( HIV), Hepatitis B 
and C screeningXIf test performed 
within 3 months prior 
to first dose of study
treatment, testing at 
screening is not 
required
Functional classification X
6Minute Walk Distance X3
Admission XParticipants may be 
admitted the day 
before dosing to 
enable completion of 
required pre -dose 
time point
assessments.
Brief physical X X
Study Treatment X 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
13ProcedureScreening 
(up to 28 
days before 
dosing)Treatment Period Follow -
up
Day 7-
14 Follow -
upDay 
28 3 
daysNotes
Pre-
dose10h 0.08h
(5 
min)20.5h 1h 2h 4h 8h 24h
Vital Signs X X X X X X X X XVital signs will be 
measured after 5 
minutes supine at all 
time points.
Triplicate blood 
pressure (BP) will be 
taken at screening
only.
Pulse Oxi metry ( SpO2) X X X X X X X X XPulse oximetry will 
be measured and 
recorded with each 
blood pressure 
assessment
Laboratory assessments 
(include liver chemistries, 
haematology panel and 
coagulation panel)X X X X
Urinalysis X X
12-lead ECG X X X X XTriplicate will be 
performed at 
Screening and Pre -
dose  
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
14ProcedureScreening 
(up to 28 
days before 
dosing)Treatment Period Follow -
up
Day 7-
14 Follow -
upDay 
28 3 
daysNotes
Pre-
dose10h 0.08h
(5 
min)20.5h 1h 2h 4h 8h 24h
Telemetry ------------------------------------------------------------------------------------- Monitoring to start 
30min prior to 
treatment 
administration and 
contin ue throughout 
the study until 24h 
after dosing
Right heart catheter 
Insertion------------------------------------------------------------------------------- RHC inserted prior to 
dose and removed 
after the 4h 
hemodynamic 
measurement
Blood sample for 
biomarkers of disease 
activityX X X X
Blood sample for Nitric 
Oxide X X X X
Blood sample for PK X X X X X X X X
Blood sample for 
immunogenicityX X XAdditional visits may 
be required. (see 
Section 9.7for 
details). 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
15ProcedureScreening 
(up to 28 
days before 
dosing)Treatment Period Follow -
up
Day 7-
14 Follow -
upDay 
28 3 
daysNotes
Pre-
dose10h 0.08h
(5 
min)20.5h 1h 2h 4h 8h 24h
Blood sample for renin -
angiotensin system
biomarkersX X X X X X X X X
Blood sample for 
pulmonary wedge RAS 
biomarkersX X X X
Hemodynamic 
measurementsX X X X
Genetic sample XCan be taken any 
time after consent 
has been signed. 
Only required once 
and
is optional.
Discharge X
AE review ================================ ==========================  X
SAE review X ============================================= ==============  X
Concomitant medication 
review4X X X
1. Pre-dose measurements may be taken any time after admission up until dosing.
2. Procedures will be completed immediately after dosing has completed. 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
163. If the six minute walk(6MW) has been perf ormed in the last 6 months, and participant has been stable on current med ication s then there is no need to repeat.  Historical data will 
be databased.
4. Concomitant medications for the 30 days prior (8 weeks prior for PAH medications) will be reviewed/recor ded at screening to evaluate eligibility and changes will be recorded 
throughout the study. 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
173. INTRODUCTION
While considerable advances have been made in treatment, PAH continues to be a 
serious, life shortening disease. PAH is characterised by  impedance to blood flow 
through the pulmonary  vasculature that occurs as a consequence of enhanced pulmonary  
vasoconstriction, small pulmonary arteriole remodelling, and loss of vessel 
compliance/distensibility  due to perivascular fibrosis [ Maron, 2013;Crosswhite ,2014]. 
Severe pulmonary  hypertension leads to right ventricular overload and right- sided heart 
failure.
GSK2586881 is a purified intravenous formulation of soluble rhACE2that isbeing 
investigated clinically  as a potential treatment for PAH.  ACE2 is a ty pe I, membrane -
bound carbox ypeptidase that inactivates Ang II b y cleaving it to produce Ang (1 -7).  Ang 
II is a key  effector peptide of the RAS that can exert deleterious effects on the pulmonary  
vasculature resulting in vasoconstriction, inflammation, proliferation and structural 
remodelling , all of which contribute to PAH development ( Lipworth, 1994, Cheng, 2005, 
Schiffrin, 2003).  Convers elyAng(1-7) signals through the Mas receptor and has shown 
vasodilatory , anti-inflammatory and anti-proliferative properties in experimental models 
(Clarke,2011).  Vasodilation induced by  Ang(1-7) has been attributed to the activation 
of endothelial nitric oxide synthase (eNOS) and the release of nitric oxide (NO) 
(Sampaio,2007). The mechanism of action of ACE2 and the downstream consequences 
are thus distinct from ACE inhibitors and angiotensin receptor blockers (Figure 1).
Systemic and pulmonary  Ang II levels have been reported to be increased in patien ts with 
idiopathic (I )PAH and are associated with increased pulmonary  vascular remodelling ( De 
Man, 2012) while serum ACE2 levels are reported to be decreased in patients with 
congenital heart disease -associated PAH, a nd correlate with mPAP (Dai,2013). The 
presence of autoantibodies to ACE2 have also been reported in the serum of patients 
with autoimmune disease with constrictive vasculopathies , PAH or persistent digital 
ischemia andcorrelate with reduced ACE2 activity  (Takahashi ,2010). Taken together 
these studies suggest ACE2 activit y may be impaired in PAH patients and 
administration of exogenous ACE2 may
 be beneficial. This is supported in rodent 
models of PAH where recomb inantACE2 has proven effective in blocking or treating 
established PAH in several rodent models, including in BMPR2-mutation related PAH 
and pulmonary  artery banding ( Johnson,
2011;Johnson,2012). 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
18Figure 1Renin-Angiotensin Sy stem
Angiotensinogen
Angiotensin I (1-10)
Angiotensin II(1-8)Angiotensin(1-9)
Angiotensin(1-7)Renin
ACE 1
AldosteroneVascular leak
Vasoconstriction
Pro-inflammatory
Pro-fibrotic /apoptotic
Sodium/water retentionACE 1ACE 2
ACE 2
Reduced vascular leak
Vasodilatation
Anti-inflammatory
Anti-proliferation/apoptotic
3.1. Study Rationale
GSK2586881 is a purified intravenous formulation of soluble rhACE2 that is being 
investigated as a potential treatment for PAH.GSK2586881 has been tested in healthy  
subjects ( Haschke,2013) and mechanically
 ventilated patients with Acute Respiratory  
Distress Sy ndrome (ARDS) (GSKstudy ACE114622; GSK Document N umber
2014N217963_00) and has been shown to be well tolerated with the rapid modulation of 
RAS peptide s.This will be the first GSK study  to test the safet y and preliminary 
hemodynamic effects of GSK2586881 in participants with PAH.
3.2. Background
PAH is defined as mPAP >25 mmHg at rest and a mean pulmonary  wedge pressure of 
≤15 mmHg ( Galie, 2009). Patients may  present with shortness of breath, swelling, 
fatigue, chest pain, and in advanced cases s yncope. Women of childbearing age are most 
commonly  affected, although PAH has been reported in children and older adults. 
Untreated PAH eventually  leads to right sided heart failure and death. PAH is a 
progressive disease, and mortality  and morbidity  remainhigh in spite of recent 
improvements in therap y.
The development of PAH is associated with connective tissue disease, liver disease, HIV 
infection, use of appetite suppressants, congenital sy stemic-to-pulmonary  shunts (e.g., 
atrial septal defect), and por tal hypertension.  PAH may  also occur with no known cause, 
in which case it is considered primary  or idiopathic PAH (IPAH), and as an inherited 
disease, referred to as heritable PAH (HPAH). IPAH is a devastating disease which if 
untreated has a median life expectancy  of 2.8 years (D’Alonzo, 1991).  Outcome for PAH 
associated with other disorders such as scleroderma is even worse .
At the histologic level, all forms of PAH are characterized by  marked structural 
remodeling o f small pulmonary  arteries (<100µ in diameter); specificall y, vascular 
smooth muscle cell proliferation (medial h yperplasia), intimal fibrosis and hyperplasia, 
and in situ microthrombosis.  I n advanced disease, plexiform lesions, likely  a disordered 
attempt at neovascularization, have been identified. These changes in the small  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
19pulmonary  arteries lead to narrowing and obliteration of the vessel lumen, increased 
resistance to blood flow, and increased strain on the right ventricle. The molecular 
mechanisms u nderlying this vasculopathy  remain poorly  understood.
Management strategies for PAH include prevention of microthrombosis using 
anticoagulants such as warfarin and promoting vasodilation and regression of muscular 
hypertrophy  and intimal fibrosis using end othelin receptor antagonists and 
phosphodiesterase (PDE) 5 inhibitors ( Humbert,2004).  In severe disease or in cases of 
treatment failure with oral therap y, prostanoids (inhaled, subcutaneous, or intravenous) 
are used. In selected patients who arenot responsive to medical therapy , lung transplant 
is an option. Despite improvement in medical therapy , only two-thirds of patients are 
alive 3 years after treatment with the most effective therap y available for PAH, 
continuous intravenous epoprostenol ( Sitbon,2002). The current therapeutic options 
remain unsatisfactory , and there remains an urgent need for novel therapies.
A detailed description of the biology , pharmacology , efficacy, and safety of 
GSK2586881 is provided in the IB(GSK Document N umber 2010N108777_03 and GSK 
Document Number2016N300457_00)
3.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reasonabl y expected AEs of GSK2586881 may be found in the IB(GSK Document
Number 2010N108777_03). 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
203.3.1. Risk Assessment
Potential Risk of Clinical 
Significanc eSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) GSK 2586881
Unknown potential for  adverse 
hemodynamic effects in patients with 
PAHPre-Clinical:
Pharmacology studies in rats showed additive reduction in BP
when GSK2 586881 at single daily dose of 1 mg/kg was given 
with an angiotensin type 1 receptor blocker or an ACE 
inhibitor.
Clinical: 
No adverse hemodynamic or BP effects noted in the first time 
in humans (FTIH) healthy volunteer study (APN01 -1-01).
No acute adver se hemodynamic effects related to study drug 
administration or considered significantly different from those 
expected of patients with ARDS in study ACE114622.Participants will be monitored including 
frequent vital signs .
Participants will be excluded if concomitant 
therapy include sthe use of an ACE inhibitor 
or angiotensin receptor blocker within 14 
days prior to dosing .
Potential Cardiov ascular(CV) Effects Pre-Clinical:
In the cynomolgus monkey study, twice daily adm inistration of 
10.4 mg/kg (20.8 mg/kg /day, highest dose given) for 12 
consecutive days resulted in a waveform abnormality in a 
single female (n=12) which was 6 premature ventricular 
complexes( PVCs ) including an episode of non- sustained 
ventricular tachycardia (NSVT) consisting of 3 consecutiv e 
PVCs (triplet).  Timing of the NSVT was 2 to 3 hours following 
the first daily dose while subsequent PVCs occurred at a Participants will be monitored including 
telemetry 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
21Potential Risk of Clinical 
Significanc eSummary of Data/Rationale for Risk Mitigation Strategy
similar time point after the second daily dose.  There was no 
evidence of QT prolongation or anatomical changes in the 
heart.
Clinica l:
No adverse effects on ECG were seen in the FTIH study 
(APN01 -1-01).
In study ACE114622 in ARDS, no clinically significant effects 
on ECG that were considered related to study drug were 
observed.
Potential for Immunogenicity Clinical:
There was no induction of an immune response to rhACE2 in 
any of the treated subjects up to 28 days after last 
administration in the FTIH healthy volunteer study (APN01 -1-
01) or in ARDS patients (ACE114622).Participants will have routine monitoring of 
any immunological response that may occur.
Unknown risk of teratogenicity Pre-Clinical:
Reproductive toxicology studies have not yet been performed 
with GSK2586881. A review of the literature suggests that 
ACE2 is present in organs of fetal mice late in gestation, and 
in the placentae of rats, guinea -pigs and humans.  Some of 
the changes noted in the PDand toxicity studies with ACE2 
are similar to those reported with an ACE inhibitor.  In 
addition, the older ACE inhibitors are known to be teratogenic 
in humans.Pregnancy testing at screening and prior to 
dosing .
Information on contraception post study will 
be provided in the informed consent form 
(ICF). 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
22Potential Risk of Clinical 
Significanc eSummary of Data/Rationale for Risk Mitigation Strategy
Potential for Rash Clinical:
In study ACE114622, rash was reported m ore frequently in 
subjects receiving GSK2586881, although only one event was 
considered drug -related.Participants will be monitored for rash in the 
clinical trials.
Study Procedures
Pulmonary arterial catheterization
(PAC)More common risks of PAC place ment include: bruising at the 
site of the PAC insertion, excessive bleeding, vein injury or 
tear or pneumothorax.  Less common complications include: 
thrombosis, infection, hypotension, arrhythmia, cardiac 
tamponade or pulmonary artery rupture.Insertion o f catheter performed by 
experienced physicians, continuous 
monitoring of pa rticipants during procedure 
per site standard operating procedures
(SOPs ).
Exposure to ionzing radiation Catheter placement may be confirmed by chest X -ray or 
fluoroscopy, as clin ically indicated. Both chest X -ray and 
fluoroscopy are assumed to increase the risk of cancer or 
heritable effects due to radiation exposure. Radiation 
exposure from chest X -ray is minimal ( 0.02mSv). Radiation 
exposure from fluoroscopy used to confirm plac ement of the 
catheter is dependent on the equipment and duration of the 
procedure . The dose will typically be around 2mSv but may
range from 2-5mSv. The additional risk of developing a fatal 
malignancy (cancer) as a result of these exposures has been 
estim ated as between 1 in 10,000 and 1 in 2000 for an adult in 
normal health.Negative pregnancy testing prior to 
procedure. Minimize fluoroscopy time; lead 
shielding per site SOPs .  Maximum exposure 
will not exceed 10mSv to confirm placement 
of the catheter . 
 
 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
233.3.2. Benefit A ssessment
All participants will undergo a thorough medical assessment during the study , 
including ECG, vital signs monitoring, and ph ysical examinations. Monitoring for 
worsening of their disease will also take place.
Participants may  benefit fr om the knowledge that they  are contributing to the process 
of developing a new treatment in an area of unmet need, even if not directl y 
beneficial for them.
3.3.3. Overall Benefit:Risk Conclusion
In clinical trials completed to date GSK2586881 has been well -tolerated and most AEs 
were mild to moderate in intensity .  The most commonly  observed AE in critically  ill 
patients has been h ypokalemia that occurred with equal frequency following 
administration of GSK2586881 and placebo.  Hypernatremia, rash, d ysphagia and 
pneumonia occurred more frequently  in subjects receiving GSK2586881 in study  
ACE114622 (GSKDocument N umber 2014N217963_00) . There have been no treatment 
related clinically  significant changes in vital signs or ECG at an y dose of GSK2586881. 
Taking into accou nt the measures taken to minimiz e risks to participants in this study , the 
potential risks identified in association with GSK2586881 are justified b y the anticipated 
benefits that may  be afforded to partic ipants with PAH.
4. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
 To evaluate change sin the pulmonary 
hemodynamics after single IV doses of 
GSK2586881 administered to participants 
with PAH receiving background PAH 
therapy. Change from baseline in p ulmonary 
vascular resistance (PVR), cardiac output 
(CO) and mean pulmonary artery pressure
(mPAP) , as data permit
Secondary
 To evaluate the safety and tolerability of 
single IV doses of GSK2586881 
administered to participants with PAH 
receiving backgrou nd PAH therapy. Adverse events (AE), clinical laboratory 
values, vita l signs, ECG , pulse oximetry 
and immunogenicity.
 To evaluate the effect of single IV doses of 
GSK2586881 on RAS peptide responses 
in participants with PAH receiving 
background PAH therap y. Change from baseline of pulmonary wedge 
and systemic RAS peptides (e.g. Ang II, 
Ang(1 -7), Ang(1 -5), and AngII/Ang (1- 7) 
ratio). 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
24Objectives Endpoints
 To evaluate the effect on biomarkers of 
disease activity after single IV doses of 
GSK2586881 administered to participants 
with PAH receiving background PAH 
therapy.  Change from baseline in NT pro -BNP, NO 
and cardiac troponin I.
 To evaluate the pharmacokinetics of 
GSK2586881 after single IV doses of 
GSK2586881 in participants with PAH 
receiving background PAH therapy. Plasma concentrations of GSK2586881 
and derived PK parameters.
Exploratory
 To evaluate PK/PD relationships after 
single IV doses of GSK2586881. Pulmonary wedge RAS peptides, and/or
pulmonary vascular hemodynamic 
measurements compared with PK 
exposure.
 To evalu ate pharmacogenetics(PGx).  Evaluate I/D polymorphisms in the 
Angiotensin Converting Enzyme (ACE) 
gene and analyze the impact on Ang II 
(and possibly other RAS peptides), and 
responses to GSK2586881 administration.
5. STUDY DESIGN
5.1. Overall Design
This is aPhase IIa,open-label, dose-escalation study in participants with PAH (as 
defined in the eligibility  criteria) whose s ymptoms have been clinicall y stable for 8 weeks 
prior to enrolment and who have had no change in PAH- specific therap y in the 12 weeks 
prior to enrolment. Eligible participants will undergo baseline assessments before 
receiving a single dose of GSK2586881 .
It is anticipated that the total duration of participation in the study  will be up to a 
maximum of 59 days from screening to last study  visit.
5.2. Number of Participants
The total number of participants recruited will be determined through an ongoing review 
of the safet y, tolerability , PK and PD data with a minimum of 4 parti cipants recruited per 
cohort. There will be 4 cohorts. At the end of e ach cohort a dose esc alation meeting will 
occur and a decision will be made whether to dose escalate.   2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
25Once dose esc alation is complete additional participants may  be recruited to further 
evaluate findings at a given dose level. A maximum of 27 participan ts will complete 
dosing and critical assessments in this study .
Evaluable participants are defined in Section 10.2.
If participants prematurely  discontinue the study , additional replacement participants may 
be recruited and assigned to the same dose level at the discretion of the Sponsor in 
consultation with the investigator.
5.3. Participant and Study  Completion
A participant is considered to have completed the study  if he/she has completed all 
phases of the stud y including the follow up visit and the last scheduled procedure shown 
in the Schedule of Activities.
The end of the stud y is defined as the date of the last visit of the last participant in the 
study.
5.4. Scientific Rationale for Study  Design
The lack of a placeb o arm is justified in that the primary  goals of this study are to 
understand the initial hemody namic effects, safety  and tolerability of GSK2586881 in a 
small number of participants with PAH. 
Due to the open label design it is accepted that there may  be potential bias in AE 
reporting, this will be taken into account when interpreting the stud y results.
5.5. Dose Justification
GSK2586881 has been studied in 21 healthy  subjects as single, intravenous doses over 30 
minutes from 0.1 mg/kg to 1.2 mg/kg, and in repeated daily doses for up to six days of 
0.4 mg/kg once a day.  In addition, ARDS patients have received four doses of 
GSK2586881: 0.1 mg/kg, 0.2 mg.kg, 0.4 mg/kg and 0.8 mg/kg over a 24 hour period 
(n=5) or 0.4 mg/kg BID for 3 day s (n=19). 
A preliminary  population PK model for GSK2586881 has been derived from data 
obtained in healthy subjects and ARDS patients and showed that the s ystemic PK profile 
was adequatel y described by a two -compartment first order elimination model and that 
the PK profile was indepe ndent of population (healthy  subjects or ARDS patients).  
Decreases in Ang II levels occurred rapidl y after GSK2586881 administration with Ang
II concentrations maximally  or near maximally  reduced at the first sampling time of 5 
minutes post -dose; consiste nt with maximal plasma concentrations of GSK2586881. The 
PK/PD response (the relationship between ACE2 and Ang II) in health y subjects and 
ARDS patients appeared to be best described with a single direct Emax model after 
accounting for differences in basel ine Ang II concentrations between healthy  subjects and 
ARDS patients.  The observation of no significant delay  between GSK2586881 
concentration and effect is in line with its mechanism of action as an enz yme on a 
substrate.   2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
26Based on the preliminary popul ation PK/PD model described above, it is predicted that 
following a single dose of ≥0.2mg/kg, Ang II concentrations will on average be reduced 
below participant baseline levels for at least 24 hours post -dose (assuming Ang II levels 
in PAH pa rticipants is consistent with levels reported in ARDS pa rticipants inGSK study  
ACE114622 ( GSK Document Number 2014N217963_00).  The 0.8mg/kg dose has been 
selected to investigate the safet y and tolerability  dose range for GSK2586881 in this 
patient population .
In an investigator -sponsored study (NCT01884 051) GSK2586881 has been studied in 3
PAH patients as a single, intravenous dose at 0.2 mg/kg, and in 2patientsat 0.4mg/kg .  
There were no SAEs and no dose limiting toxicities were observed . 
6. STUDY POPULA TION
Prospective approval of protocol deviations t o recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply:
Age
1.Participant must be between 18-75 years of age (inclusive), at the time of signing the 
informed consent.
Type of Participant and Disease Characteristics
2.Documented diag nosis of PAH, defined as mPAP > 25 mmHgand PWP ≤15 
mmHg.
3.Idiopathic pulmonary  arterial h ypertension (I PAH), hereditary  pulmonary  arterial 
hypertension (HPAH), or PAH associated with collagen vascular disease, or appetite 
suppressant use. 
Note: Those with portopulmonary  hypertension or pulmon ary veno-occlusive 
diseas (PVOD) are not eligible for the study
4.World Health Organization (WHO) functional class I , II, or III, stable for at least 8 
weeks prior to enrollment.
5.Hemodynamically stable on background therap y with noevidence of uncontrolled 
right heart failure (historic data), as determined b y the investigator . 
6.Six minute walk (6MW) distance, as perf ormed at screening or within 6 months prior 
to screening, of ≥ 100 meters and ≤ 500meters.
7.Mean BPof >60 mmHg
8.Receiving stable doses of one or more medications that are approved for treatment of 
PAH, including endothelin receptor antagonists, phosphodiesterase 5 inhibitors,  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
27and/orprostanoids /prostacyclin receptor agonists, for a minimum of 12 consecutive 
weeks before enrollment. 
NOTE:Anticoagulant therap y can be adjusted according to target INR
9.Diuretic dose stable for 8 weeks.
Weight
10.Body weight ≤100kg and body  mass index (BMI) within the range 18 -35kg/m2
(inclusive).
Sex
11.Male and/or female (following confirmation of negative pregnancy test for 
WOCBP) .  Women who are pregnant or breastfeeding are excluded .
Informed Consent
12. Capable of giving signed informed consent as described in Appendix 3 which 
includes compliance with the requirements and restrictions listed in the ICF and in 
this protocol.
6.2. Exclusion Criteria
Participants are excluded from the study  if any of the following criteria apply :
Medical Conditions
1.History of systemic h ypotension, defined as s ystolic BP < 90 mmHg and/or diastolic 
BP <50 mmHg.
2.Hospitalization for PAH associated deterioration in the previous 6 months. 
3.Any additional medical condition, serious intercurrent illness, or other extenuating 
circumstance that, in the opinion of the I nvestigator, may  significantly  interfere with 
study compliance, including all prescribed evaluations and follow -up activities. 
Concurrent disease or condition that may  interfere with study  participation or safet y 
include bleedi ng disorders, arrh ythmia, organ transplant, organ failure, current 
neoplasm, poorly  controlled diabetes mellitus, and serious neurological disorders.
4.Complex repaired and unrepaired congenital heart disease.
5.Subjects with Eisenmenger ph ysiology.
6.Alanine tr ansferase (ALT) >2x upper limit of normal (ULN).
7.Bilirubin >1.5xUL N (isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%).
8.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones).
9.Estimated glomerular -filtration-rate(eGFR)<45mL/min/1.73m2.
10.QTc >480 msec or QTc > 500 msec in participants with bundle branch block.
NOTES:  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
28The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over-read.
The specific formula used to determine eligibility  and discontinuation for an 
individual participant should be determined prior to initiation of the study . In 
other words, several different formulas cannot be used to calculate the QTc for an 
individual participant and then the lowest QTc value used to include or 
discontinue the participant from the trial.
11.Any bleedingconcerns as evidenced b y INR >1.5 (in participants not receiving 
anticoagulation therap y) or platelet count < 80,000.
12.Hb<10 g/dL
Prior/Concomitant Therapy
13.Sensitivity  to any of the study treatments, or components thereof, or drug or other 
allergy that, in the opinion of the investigator or Medical Monitor, contraindicates 
participation in the study .
14.Any use of an ACE inhibitor, angiotensin receptor blocker, or renin inhibitors within 
14 days prior todosing.  Therap y can be stopped to enable inclusion if deemed safe 
by the participant’s treating ph ysician.
Prior/Concurrent Clinical Study Experience
15.Use of an y investigational product (IP) or device within 30 day s prior to dosing, or 
known requirement for any  investigational agent prior to completion o f all scheduled 
study assessments.
Diagnostic assessments
16.Positive HI Vantibody test.
17.Presence of Hepatitis B surface antigen (HBsAg) at screening. 
18.Positive Hepatitis C antibody  test result at screening or within 3 months prior to 
starting stud y treatment .
NOTE:  Participants with positive Hepatitis C antibody  due to prior resolved 
disease can be enrolled, only  if a confirmatory  negative Hepatitis C ribonucleic 
acid(RNA)test is obtained .
19.Positive Hepatitis C RNA test result at screening or within 3 month s prior to first 
dose of study  treatment.
NOTE: Test is optional and participants with negative Hepatitis C antibody test 
are not required to also undergo Hepatitis C RNA testing .
Other Exclusions
20.Participation in the study would result in loss of blood or blood products in excess of 
300mL within 65 days. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
2921.Exposure to more than 4 new chemical entities within 12 months prior to the first 
dosing day .
22.A known or suspected history  of alcohol or drug abuse within the 2 y ears prior to 
screening
23.Unable to refrain f rom smoking during the in -house treatment period.
6.3. Lifestyle Restrictions
6.3.1. Caffeine, A lcohol, and Tobacco
Participants will abstain from ingesting caffeine -or xanthine -containing products 
(eg, coffee, tea, cola drinks, and chocolate) for 2 hoursbefore the start of dosing.
Participants will abstain from alcohol for 24 hours before the start of dosing until 
after collection of the final PK and/or PDsample. 
Participants who use tobacco products will be instructed that use of nicotine -
containing products (inc luding nicotine patches) will not be permitted while they  are 
in the clinical unit .
6.3.2. Activity
Participants will abstain from strenuous exercise for 24hours before each blood 
collection for clinical laboratory  tests. Participants may  participate in light 
recreational activities during studies ( e.g., watching television, reading).
6.3.3. Contraception Requirements
Specific requirements for contraception can be found in Appendix 5and will be provided 
in the informed consent form (ICF).
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y enrolled in the study . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory  authorities. Minimal information 
includes demograph y, screen failure details, eligibility  criteria, and an y serious adverse 
events (SAE s).
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened once. Rescreened participants should be assigned a new participant 
number. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
307. TREATMENTS
Study treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo,or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
7.1. Treatments A dministered
Study Treatment Name: GSK2586881
Dosage formul ation: Clear , colorless liquid
Unit dose strength(s)/Dosage level(s): Unit dose strength: 5 mg/mL
Up to 0.8mg/kg
Route of Administration IV 
Dosing instructions: IV push over 3 -5 minutes
Packaging and Labeling Study Treatment will be provided in 
frozen vials. Each vial will be labeled as 
required per country requirement.
Manufacturer Polymun/GSK
7.2. Dose Modification
The study  will comprise of 4 separate cohorts.  Participants will be administered a single 
dose of one of the following planned doses: 0.1, 0.2, 0.4, or 0.8mg/kg. 
Dose escalation will occur after a minimum of 4participants have been dosed per cohort 
and review of safet y, tolerability , PK and hemodynamic data up to 24h post dose has 
taken place. Dose escalation will continue up to a max imum dose of 0.8mg/kg. 
Cohort sizes may  vary with a minimum of 4 participants per cohort. Additional 
participants may  be enrolled to expand a dosing cohort to further evaluate findings at a 
given dose level.
If a subject experiences a dose limiting toxici ty (DLT)that is considered at least possibly  
related to stud y drug, dosingof additional participants will be halted and a full safet y 
review will be performed to confirm causalit y.  If 2 participants in an y cohort experience  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
31a DLTconsidered at least pos sibly related to study  drug, the maximum tolerated dose 
(MTD) has been exceeded.
Dose limiting toxicities are defined as toxicities that, due to their severity  or duration, are 
considered unacceptable, and limit further dose escalation.  Examples of DLT’s include,
but are not limited to :
Severe headache unrelieved by  nonsteroidal anti -inflammatory  drugs (NSAIDS)
Nausea/Vomiting
Hypotension as defined by mean arterial pressure <60mmHg or a drop in sy stolic 
BPof 25%
7.3. Method of Treatment A ssignment
As this is an open label study, participants will be assigned to the ongoing treatment 
group at that time.
Study using 
IWRSAll participants will be assigned to a treatment group using an 
Interactive Web Response Sy stem (IWRS). Before the study  starts, 
the log in in formation & directions for the IWRS will be provided to 
each site.
Study treatment will be dispensed at the study  visits summarized in 
SOA.
7.4. Blinding
Open-label using 
IWRSThis is an open -label study ; however, the specific dose level to be 
taken by a participant will be assigned using an IWRS to aid 
cohort management . The site will contact the I WRS prior to the 
start of study  treatment administration for each participant. The 
site will record the treatment assignment on the applicable case 
report form (CRF), if required. 
7.5. Preparation/Handling/Storage/A ccountability
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolve d before use of the study  treatment.
Only participants enrolled in the study  may receive study  treatment and only  
authorized site staff may  supply or administer study  treatment. All study  treatments 
must be stored in a secure, environmentall y controlled, a nd monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
32The investigator, institution, or the head of the medical institution (where applicable) 
is respons ible for stud y treatment accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).
Further guidance and information for the final disposition of unused study  treatment 
are provided in the Study Ref erence Manual. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact and the generation of aerosols or mists. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or 
GSK study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be pro vided to the 
investigator, where this is required b y local laws, or is available upon request from 
GSK.
7.6. Treatment Compliance
GSK2586881 will be intravenously administered to participants at the site.  
Administration will be documented in the source docume nts and reported in the 
CRF.
When the individual dose for a participant is prepared from a bulk supply , the 
preparation of the dose will be confirmed b y a second member of the stud y site staff. 
When participants are dosed at the site, they  will receive s tudy treatment directl y 
from the investigator or designee, under medical supervision.  The date and time 
(start and end time of infusion) of the dose administered in the clinic will be recorded 
in the source documents.  The dose of stud y treatment and stud y participant
identification will be confirmed at the time of dosing by  a member of the study  site 
staff other than the person administering the stud y treatment.  
7.7. Concomitant Therapy
Any medication or vaccine (including over -the-counter or prescription m edicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the stud y must be recorded along with:
reason for use
dates of administration including start and end dates
dosage information inc luding dose and frequency
The Medical Monitor should be contacted if there are an y questions regarding 
concomitant or prior therapy .
No medications will be prohibited except for those listed below : 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
33ACE inhibitors, angiotensin receptor blockers, and renin i nhibitors will be 
discontinued at least 14 day s prior to dosing until 72 hours post dose.
Paracetamol/Acetaminophen, at doses of 2grams/day , is permitted for use any  time 
during the stud y. Other concomitant medication may be considered on a case -by-case
basis by the investigator in consultation with the Medical Monitor if required.
7.8. Treatment after the End of the Study
Participants will not receive an y additional treatment from GSK after completion of the 
study because other treatment options are availabl e.
The investigator is responsible for ensuring that consideration has been given to the post -
study care of the participants medical condition, whether or not GSK is providing specific
post-study treatment.
8. DISCONTINUA TION CRIT ERIA
There areno treatment discontinuation criteria as this is a single dose study . 
8.1. Liver Chemistry  Monitoring
Liver chemistry  monitoring criteria have been designed to assure participant safet y and 
evaluate liver event etiology,(in alignment with the Food and Drug Administration(F DA)
premarketing clinical liver safety  guidance). These protocol guidelines are in alignment 
with FDA premarketing clinical liver safety  guidance:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf .
Liver Safety Required Actions and Follow up Assessments Section can be found in 
Appendix 7 .
8.2. QTc Monitoring Criteria
There are no treatment discontinuation criteria as this is a single dose study , however the 
following criteria described below still apply . 
The sameQT correction formula must be used for each individual participant to 
determine eligibility  for and discontinuation from the study .  This formula may  not 
be changed or substituted once the participant has been enroll ed.
For example, if a participant is eligible for the protocol based on QTcB, then 
QTcB must be used for discontinuation of this individual participant as well.
Once the QT correction formula has been chosen for a participant’s eligibility , 
the same formul amust continue to be used for that participant for all QTc data 
being collected for data analysis .  Safety ECGs and other non -protocol specified 
ECGs are an exception.   2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
34The QTc should be based on averaged QTc values of triplicate ECGsobtained over a 
brief (e.g., 5 -10 minute) recording period.  
A participant who meets either bulleted criteria based on the average of triplicate ECG 
readings will receive additional monitoring as appropriate :
QTc > 530msec OR Uncorrected QT > 600 msec
Change from baseline of QTc > 60 msec
8.3. Withdrawal from the Study
Participants who withdraw from the study  aftertreatment will still be required to 
complete both follow -up visits as detailed in the SoA.
A participant may  withdraw from the study  at any time at his/her own reques t, 
or may be withdrawn at any  time at the discretion of the investigator for safety , 
behavioural , compliance or administrative reasons.   This applies to withdrawal 
from the genetic substudy.
If the participant withdraws consent for disclosure of future inf ormation, the 
sponsor may retain and continue to use any  data collected before such a 
withdrawal of consent.   This applies to withdrawal from the genetic substudy .
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study records.
If a participant is withdrawn from the stud y every effort must be made to 
complete the follow -up assessments detailed in the SoA within 7 -14 days of last 
doseand the Day 28 follow -up assessments .
8.4. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study site. 
The following actions must be taken if a particip ant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of maintaining 
the assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee 
must make every  effort to regain contact with the participant (where possible, 3 
telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact attempts should be 
documented in the participant’s medical record. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
35Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Study procedures and their timing are summarized in the SoA (Section 2). 
Protocol waivers or exemptions are not allowed 
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will main tain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obta ined before signing of ICF may be utilized for screening or 
baseline purposes provided the procedure met the protocol- specified criteria and was 
performed within the time frame defined in the SoA.
The maximum amount of blood collected from each participant over the 
duration of the study , including any  extra assessments that may  be required, will 
not exceed 300mL.
Repeat or unscheduled samples may be taken for safet y reasons or for technical 
issues with the samples.
9.1. Pharmacody namics
9.1.1. Hemodynamics
Pulmonary  arterial catheters will be placed in all participants enrolled .Participants will 
consent to have the catheter inserted for the purposes of the study .Catheter placement 
may be confirmed by  chest X-ray or fluoroscopy , as clinically  indicated .  All effort wi ll 
be made to m inimize radiation exposure time .
Variables that will be recorded from the right heart catheterization, as data permit, 
include: 
right atrial pressure
pulmonary  artery systolic and diastolic pressure
mean pulmonary  artery pressure
pulmonary wedge pressure
cardiac output and index measured b y thermodilution  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
36pulmonary  vascular resistance (PVR)
pulmonary  artery oxygen saturation (PAsat)
The clinical sites will use their SOPs for the insertion, maintenance and removal of the 
catheter.  The cath eter will be removed following completion of the “4 hour post- dose” 
catheter measurements and sample collections. The participant will then be monitored for 
a minimum of 20 hours or until discharge.
9.2. Adverse Events
The definitions of an AE or SAE can be fou nd in Appendix 4 .
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serio us, considered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  (see Section 8). 
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAEswillbe collected from the signing of the ICF until the follow- up visit
at the time points specified in the SoA (Section 2).
All AEs will be collected from the start of treatment until the follow -up visit at 
the time points specified in the SoA (Section 2).
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditio ns section of the CRF not the AE section.
All SAEswill be recorded and reported to the sponsor or designee within 24 
hours, as indicated in Appendix 4 . The investigator will submit any  updated 
SAE data to the sponsor within 24 hours of it being available.
Investigators are not obligated to activel y seek AEs or SAEs in former study  
participants. However, if the investigator learns of any SAE, including a death, 
at any time after a participant has been discharged from t he study, and he/she 
considers the event to be reasonabl y related to the study  treatment or study  
participation, the investigator must promptly  notify the sponsor.
The method of recording, evaluating, and assessing causality  of AEs and SAEs
and the procedu res for completing and transmitting SAE reports are provided in 
Appendix 4 .
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal que stioning of the participant is the preferred method to inquire about 
AEoccurrence.  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
379.2.3. Follow-up of AEs and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, wil l be followed until the event is 
resolved, stabilized, otherwise explained, or the participant is lost to follow- up (as 
defined in Section 8.4). Further information on follow -up procedures is given in 
Appendix 4 .
9.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and t he safety of a study  treatment under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify both the local regulatory  
authority and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
IRB/ IEC, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR ) according to local regulatory  requirements and 
sponsor policy and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information ( eg, summary  or listing of SAE) fr om the 
sponsor will review and then file it along with the IBand will notify  the 
IRB/IEC, if appropriate according to local requirements.
9.2.5. Cardiovascular and Death Events
For any CVevents and all deaths, whether or not they  are considered SAEs, specific CV
and Death sections of the CRF will be required to be completed. These sections include 
questions regarding CV (including sudden cardiac death) and non- CVdeath. 
The CV CRFs are presented as queries in response to reporting of certain CV medical 
dictionary for regulatory  activities (MedDRA )terms.The CV information should be 
recorded in the specific CVsection of the CRF within one week of receipt of a CV Event 
data query  prompting its completion. 
The Death CRF is provided immediately  after the occu rrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
389.2.6. Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of 
male participants will be collected after the start of study  treatment and until 1 week
after dose.
If a pregnancy  is reported, the investigator should inform GS Kwithin 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 5.
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, and ectopic pregnancy ) are considered SAE.
9.3. Treatment of Overdose
For this study , any dose of GSK2586881 greater than 1.2mg/kgwill be considered an 
overdose.
Sponsordoes not recommend specific treatment for an overdose.
In the event of an overdose, the investigator/treating ph ysician should:
1.Contact the Medical Monitor immediately .
2.Closely monitor the participant fo r AE/SAE and laboratory  abnormalities until 
GSK2586881 can no longer be detected s ystemically (at least 3dayspost last dose ).
3.Obtain a plasma sample for PK anal ysis as described in the SoA (Section 2).  PK 
assessments may  be continued bey ond 24 hours if requested b y the Medical Monitor 
(determined on a case -by-case basis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or mod ifications will be made by  the investigator 
in consultation with the Medical Monitor based on the clinical evaluation of the 
participant.
9.4. Six-Minute Walk Test
Six minute walk (6MW) distance, as performed at screening or withi n 6 months prior to 
screening. The subject is asked to walk along a prescribed path (t ypically 30 meters long) 
as far as possible during a 6- minute interval. The subject may  walk at whatever pace is 
comfortable, with the goal of walking the longest distance possible. The subject may  rest 
as needed.  The subject will need to walk a minimum distance of  100 meters and 
maximum distance of ≤500metersto meet study  inclusion criteria. The distance walked 
will be entered into the CRF.
9.5. Safety Assessments
Planned time points for all safety  assessments are provided in the SoA (Section 2). 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
399.5.1. Physical Exa minations
A complete ph ysical examination will include, at a minimum, assessments of the 
Skin, CV, Respiratory , Gastrointestinal and Neurological s ystems. Height and 
weight will also be measured and recorded (at screening only ).
A brief ph ysical examinatio n will include, at a minimum, assessments of the 
skin, lungs, CV system, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
9.5.2. Vital Signs
Pulse rate, respiratory  rate, and BPwill be assessed.
Blood pressure and pulse measurements will be assessed (supine)with a 
completely  automated device. Manual techniques will be used only  if an 
automated device is not available.
Blood pressure and pulse measurements should be preceded b y at least 5 
minutes of rest for the participant in a quiet setting without distractions (eg, 
television, cell phones). At screening there will be 1 pulse and 3 BP
measurements (3 consecutive BPreadings will be recorded at intervals of at 
least 1 minute). The average of the 3 BPreadings will be recorded on the CRF.
9.5.3. Pulse Oximetry
Oxygen saturation will be measured by  pulse oximetry  after the subject has been 
at rest for at least 5 minutes.
9.5.4. Electrocardiograms
12-lead ECG will be obtained using an ECG machine t hat automatically  
calculates the HRand measures PR, QRS, QT, and QTc intervals. Refer to 
Section 8.2for QTc monitoring criteria and additional QTc readings that may  be 
necessary .
Triplicate ECG are required at screening and predose . At these time points, 3
individual ECG tracings should be obtained as closely  as possible in succession, 
but no more than 2 minutes apart. 
9.5.5. Telemetry
Telemetry  will be measured continuously  asdetailed in the SoA (Section 2).
Only AE and SAE data related to telemetry  will be databased.
9.5.6. Clinical Safety Laboratory  Assessments
Refer to Appendix 2for the list of clinical laboratory  tests to be performed and 
to the SoA (Section 2)for the timing and frequency .  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
40The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be more severe th an expected for the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within 3days after the last dose of study  
treatment should be repeated until the values return to normal or baseline or are 
no longer considered significantly  abnormal by  the investigator or medical 
monitor. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identifi ed and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA.
If laboratory  values from non- protocol spec ified laboratory  assessments 
performed at the institution’s local laboratory  require a change in participant 
management or are considered clinically  significant by  the investigator (eg, SAE 
or AE or dose modification), then the results must be recorded in the CRF.
9.6. Pharmacokinetics
Whole blood samples will be collected for measurement of plasma concentrations of 
GSK2586881 as specified in the SoA (Section 2).The actual date and time (24 -hour 
clock time) of each sample will be recorded.
Additional sample time points may be added during the study  if warranted and agreed 
upon between the investigator and the sponsor , however, the maximum allowed blood 
volume will not be exceeded . 
Samples collected for analy ses of GSK2586881 plasma concentration may also be used 
to evaluate safet y or efficacy aspects related to concerns arising during or after the study.
Once the plasma has been anal yzed for GSK2586881 any remaining plasma may be 
analyzed for other compound -related metabolites and the results reported under a 
separate protocol.
Details of blood sample collection (including volume to be collected), processing, storage 
and shipping procedures are provided in the lab manual.
Plasma analy sis will be performed under the c ontrol of GSK, the details of which will be 
included in the lab manual . 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
419.7. Immunogenicity  Assessments
Whole blood samples will be collected for measurement of immunogenicity assessments 
as specified in the SoA (Section 2). 
Additional visits at 12, 24, and 36 weeks post- dose (and less frequently  thereafter), to 
obtain immunogenicity  samples may  be required in the unlikely  event that subjects 
develop a clinicall y relevant immunoglobulin response to the drug as desc ribed in the lab 
manual.
Details of immunogenicity blood sample collection (including volume to be collected), 
processing, storage and shipping procedures are provided in the lab manual.
9.8. Biomarkers
The following samples for biomarker research will be collected from all participants in 
this study  as specified in the SoA (Section 2):
RAS peptides Ang II, Ang (1 -7)and Ang (1-5) and other vasoctive peptides in 
theRAS and bradykinin cascade, and Nitric Oxide may be analyzed from 
plasma as data permit.
Biomarkers of disease activity : NT pro-BNP, and cardiac troponin I may  be 
analyzed from serum as data permit.
Additional sample time points may  be added during the stud y if warranted and agreed 
between the investigator and the sponsor, however themaximum allowed blood volume 
will not be exceeded.
In addition, with the participant’s consent, samples will be stored and may  be used to 
investigate additional biomarkers thought to play  a role in PAH disease progression or to
evaluate their association with observed clinical responses to GSK2586881.
Samples may  alsobe used for research to develop methods or support identification of 
prognostic/diagnostic biomarkers associated with clinical outcomes in PAHand related 
diseases.
Details of blood sample collection (including volume to be collected), processing, storage 
and shipping procedures are provided in the lab manual.
9.9. Genetics
A 6mL blood sample for deoxyribonucleic acid (DNA)isolation will be collected from 
participants who have consented to participate in the genetics anal ysis component of the 
study. Participation is optional. Participants who do not wish to participate in the genetic 
research may  still participate in the study .
In the event of DNA extraction failure, a replacement genetic blood sample may  be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
42Appendix 6for Information regarding genetic research . Details on processes for 
collection and shipment and destruction of these samples can be found in SRM. 
10. STATISTICA L CONSIDER ATIONS
10.1. Sample Size Determination
The sample size chosen isnot based on statistical considerations.  
The design of the study is deemed acceptable under the anticipated safety  profile, given 
previous clinical experience with GSK2586881. 
If additional participants/cohorts are enrolled to allow for evaluation of additional dose 
levels the proposed anal ysisapproach(s) would be modified accordingl y. 
10.2. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF
Safety All participants who take at least 1 dose of study treatment. 
Participants will be analyzed according to the treatment they actually 
received.
Evaluable All participants who are in the Safety population who complete all 
Day 1 assessments (including up to 24 hours post dose) and were 
not deemed to ha ve had major protocol deviations (as defined within 
the PDMP)
PK Population Subjects in the ‘Safety ’ population for whom a PKsample was 
obtained and analysed.  PK population will be the population for 
reporting PK data.
10.3. Statistical A nalyses
Limited subj ect level data/information from a GSK supported study  ([STUDY_ID_REMOVED]) is 
available at doses of 0.2 mg/kg and 0.4 mg/kg.  This data may  be used as supportive only  
in reference to basic comparisons of safety , PK and PD with the current study .  This 
previous st udy data will not be incorporated into statistical analy ses associated with the 
current stud y. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
4310.3.1. Pharmacody namic and Safety Analyses
Endpoint Statistical Analysis Methods
Primary Descriptive Summaries , Figures and Listings of Change from 
Baseline PVR , CO an d mPAP by planned timepoints . 
If data permit, linear regression of Dose vs Change from Baseline 
PVR, CO and/or mPAP at 4 hours (endpoints log etransformed if 
necessary ).
Secondary Descriptive Summaries , Figures and Listings. 
Simple figures (e.g. scatter plots and/or scatterplot matrix plots) 
exploring correlation between ke yPD endpoints (e.g. RAS peptides) 
and the Primary endpoint s(PVR, CO andmPAP ).
All safety analyses will be performed on the Safety Population
Exploratory Will be describe d in the RAP.  Note that exploratory genetic analyses, should 
they occur will be detailed in a separate RAP.
10.3.2. Pharmacokinetic and Pharmacokinetic -Pharmacodynamic
Analyses
Pharmacokinetics anal ysis will be performed b y, or under direct auspices of the Clinical 
PKModeling & Simulation departm ent within GSK .  Plasma GSK2586881 
concentration -time data will be anal yzed by non-compartmental methods with 
WinNonlin V6.3 or greater.  Calculations will be based on the actual sampling times 
recorded during the study . 
From the plasma concentration -time data, the following PKparameters will be 
determined, as data permit: maximum observed plasma concentration (Cmax), time to 
Cmax (tmax), area under the plasma concentration -time curve [AUC(0- t) andarea under 
the concentration -time curve from time zero (pre -dose) extrapolated to infinite time 
[AUC(0-∞)], the last observed quantifiable concentration (Clast), time of the last 
quantifiable concentration (tlast), plasma clearance (CL), volume of distribution (V D) and 
apparent terminal phase half -life (t1/2).  Other PK parameters may  also be determined.
Pharmacokinetic data will be presented in graphical and/or tabular form and will be 
summarized descriptively. All PKdata will be stored in the Archives, GSK
Pharmaceuticals, research and development ( R&D). 
Apopulation PK analy sis maybe conducted .  In addition the GSK2586881 plasma 
concentration -time data may  be merged with historical data and anal ysed as part of a 
population PK meta -analysis. Further details will be provided in the RAP . If data permit, 
potential association between s ystemic exposure of GSK2586881 and identified 
biomarker (e .g.AngII, Ang(1-7) , Ang(1-5)), and/or clinical related endpoints 
(pulmonary  vascular hemody namic) may  be studied.  I n addition the PK/PD data may  be  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
44merged with historical data and anal ysed as part of a population PK/PD (biomarker) 
meta-analysis. Further details will be provided in the RAP. Population PK and PK/PD 
exploratory  analyses may be presented separatel y to the CSR.
10.3.3. Interim A nalyses
Safety, PK andpulmonaryhemodynamicdata will be reviewed after 4 subjects have 
completed dosing in each cohort prior to dosing at the next level. Alinear regression 
model may  be fitted to the (log transformed , if necessary ) Change from Baseline at 4h 
PVR, CO and/or mPAP data from the first three cohorts (Dose Vs baseline adjusted 
response); and the slope parameter estimated along with the (extrapolated) mean response 
for the planned 4thdose of 0.8mg/kg. This will be used in addition to safety, PK and other 
PD data, to aid the team in decision making with regards to additional subject recruitment 
at an optimum dose level(s).
The RAPwill describe the planned interim analy ses in greater detail. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
4511. REFERENCES
Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascu lar inflammation. Medical 
Science Monitor. 2005; 11:194 –205.
Clarke NE and Turner AJ. Angiotensin- Converting Enzy me 2: The First 
Decade.International Journal of Hy pertension. 2011; doi:10.1155/2012/307315
Crosswhite P, Sun Z. Molecular Mechanisms of Pulmon ary Arterial Remodeling. 
Molecular Medicine .2014; 20(1): 191–201.
D’Alonzo E, et al. Survival in Patients with Primary  Pulmonary  Hypertension. Annals of 
Internal Medicine . 1991;15(5):343-349
Dai HL, Guo Y, Guang XF, Xiao ZC, Zhang M, Yin XL . The changes of serum 
angiotensin- converting enzy me 2 in patients with pulmonary  arterial hy pertension due to 
congenital heart disease. Cardiology . 2013;124(4):208 -12.
De Man F, Tu, Handoko, et al. Dy sregulated Renin- Angiotensin- Aldesterone Sy stem 
Contributes to Pulmonar y Arterial Hy pertension. American Journal of Respiratory  and 
Critical Care Medicines. 2012;186(8):780 -9
Galie N, et al. Guildines for the diagnosis and treatment of pulmonary  hypertension. 
European Respiratory  Journal. 2009; 34(6):1219-63
GlaxoSmithKline D ocument Number 2010N108777_03 Study  ID 
GSK2586881.I nvestigator's Brochure for GSK2586881 (formerl y known as APN01) –A 
Soluble Recombinant Human Angiotensin Converting Enzy me 2 (rhACE2). Report Date 
18-Sep-2015
GlaxoSmithKline Document Number 2014N217963_00 Study ID ACE114622 . A two 
part study  to investigate the safet y, tolerability , pharmacokinetics and pharmacody namics 
of GSK2586881 in subjects with acute lung injury. Report Date 07 -Oct-2015. 
GlaxoSmithKline Document Number 2016N300457_00 Supplement to GS K2586881 
Investigator’s Brochure. Version 2.  Report Date 07- Oct-2016.
Grobe JL, Mecca AP, L ingis M, Shenoy  V, Bolton TA, Machado JM,et.al. Prevention of 
angiotensin induced cardiac remodeling b y angiotensin- (1–7). American Journal of 
Physiology. Heart and Circulatory Physiology . 2007;292(2):H736 –H742.
Haschke M, Schuster M, Poglitsch M, L oibner H, Salzberg M, Bruggisser M, et al. 
Pharmacokinetics and pharmacod ynamics of recombinant human angiotensin -converting 
enzyme 2 in healthy  human subjects. Clinical P harmacokinetics. 2013 Sep;52(9):783-92.
Humbert 2004 Marc Humbert, M.D., Ph.D., Olivier Sitbon, M.D., and Gérald 
Simonneau, M.D. Treatment of Pulmonary  Arterial Hy pertension, The New England 
Journal of Medicine .  2004;351:1425 -36. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
46Johnson JA, Hemnes AR, Pe rrien DS, et al. C ytoskeletal defects in Bmpr2- associated 
pulmonary  arterial hy pertension. American Journal of Physiology -Lung 
CellularandMolecular Physiology . 2012;302:L 474-84
Johnson JA, West J, Maynard KB, Hemnes AR. ACE2 improves right ventricular 
function in a pressure overload model. PLoS One . 2011;6(6):e20828
Lipworth BJ, Dagg KD. Vasoconstrictor effects of angiotensin II on the pulmonary  
vascular bed. Chest. 1994; 105(5):1360–1364.
Maron BA, Loscalzo J. Pulmonary  hypertension: pathophy siology and signaling 
pathways. Handbook of Experimental Pharmacology. 2013;218:31 -58.
Sampaio WO, Santos RA, Faria -Silva R, da Mata Machado LT, Schiffrin EL, Touy z RM. 
Angiotensin- (1–7) through receptor Mas mediates endothelial nitric oxide sy nthase 
activation via Ak t-dependent pathway s. Hypertension 2007;49(1):185 –192.
Schiffrin EL, Tou yz RM. Inflammation and vascular hy pertrophy induced by angiotensin 
II: role of NADPH oxidase -derived reactive ox ygen species independentl y of blood 
pressure elevation? Arteriosclerosi s, Thrombosis, and Vascular Biology . 2003; 23:707–
709. 
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et.al. Long -Term 
Intravenous Epoprostenol I nfusion in Primary  Pulmonary  Hypertension. Journal of the 
American College of Cardiology. 2002;40(4)
Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin -converting 
enzyme 2 in patients with connective tissue diseases. Arthritis Research & Therapy.
2010;12(3):R85
Tipnis SR , Hooper NM , Hyde R, Karran E, Christie G & Turner AJ . A human homolog 
of angiotensin- converting enz yme. Cloning and functional expression as a captopril -
insensitive carbox ypeptidase . The Journal of Biological Chemistry . 2000; 275 , 33238–
33243.
Vickers C , Hales P, Kaushik V , Dick L, Gavin J, Tang Jet al. Hydrolysisof biological 
peptides by  human angiotensin -converting enz yme-related carbox ypeptidase . The Journal 
of Biological Chemistry . 2002;277, 14838–14843.
Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzy me 
determines plasma clearance of an giotensin- (1–7). Hypertension.1998; 32(3):496 –502.
Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin -(1–7) on 
vascular smooth muscle cell proliferation and migration. PLoS ONE. 2010;5(8):e12323. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
4712. APPENDICES
12.1. Appendix 1: A bbreviat ions and Trademarks
ABBREVIA TIONS
2D Two-dimensional
6MW Six minute walk
ACE2 Angiotensin converting enzy me type 2
AE Adverse Event
ALT Alanine aminotransferase (SGPT)
Ang II Angiotensin II
ARDS Acute respiratory  distress sy ndrome
AST Aspartate amin otransferase (SGOT)
aPTT Activated prothrombin time
AUC(0-)Area under the plasma concentration -time curve 
AUC(0-t)Area under the concentration- time curve from time zero (pre -dose) to 
last time of quantifiable concentration within a subject across a ll 
treatments
BID Bi-Daily
BMI Body mass index
BP Blood pressure
BUN Blood urea nitrogen
CIOMS Council for International Organizations of Medical Sciences
Clast Last observed quantifiable concentration
CL Plasma clearance 
Cmax Maximum observed pl asma concentration 
CO Cardiac output
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic Obstructive Pulmonary  Disease
CPK Creatine phosphokinase
CRF Case Report Form
CRM Continual reassessment model
CSR Clinical study  report
CV Cardiovascular 
DLT Dose limiting toxicity
DNA Deoxyribonucleic acid
ECG Electrocardiogram
eCRF Electronic case report form
eGFR Estimated glomerular -filtration-rate
FDA Food and Drug Administration
FSH Follicle Stimulating Hormone
FTIH First time in hum ans
GCP Good Clinical Practice
GFR Glomerular -filtration-rate
GSK GlaxoSmithKline 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
48HB hemoglobin
HBsAg Hepatitis B surface antigen
hCG Human chorionic gonadotropin
HIPAA Health Insurance Portability  and Accountability
HIV Human Immunodeficiency  Virus
HPAH Heritable PAH
HPLC High performance liquid chromatograph y
HR Heart rate
HRT Hormone replacement therap y 
IB Investigator’s Brochure
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use
ICF Informed Consent Form 
IEC Independent Ethics Committee
IgG Immunoglobulin G
IgM Immunoglobulin M
IND Investigational New Drug
INR International normalized ratio
IP Investigational Product
IPAH Idiopathic PAH
IRB Institutional Review Board
IUD Intrauterine device
IUS Intrauterine hormone -releasing s ystem
IV Intravenous
IWRS Interactive Web Response Sy stem
LDH Lactate deh ydrogenase
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MedDRA Medical Dictionary for Regul atory Activities
mPAP Mean pulmonary  arterial pressure
MSDS Material Safet y Data Sheet
MTD Maximal tolerated dose 
NO Nitric oxide
NSAIDS Nonsteroidal anti -inflammatory  drugs
NSVT Non-sustained ventricular tachy cardia
PAC Pulmonary  arterial catheter ization
PAH Pulmonary  Arterial Hy pertension
PAP Pulmonary  arterial pressure
PAsat Pulmonary  artery saturation
PCW Pulmonary  capillary wedge
PD Pharmacod ynamic
PDE Phosphodiesterase
PDMP Protocol Deviation Management Plan 
PGx Pharmacogenetics
PK Pharmacokinetic
PT Prothrombin time 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
49PVC Premature Ventricular Complexes
PVR Pulmonary  vascular resistance
QTcB QT duration corrected for heart rate b y Bazett’s formula
QTcF QT duration corrected for heart rate b y Fridericia’s formula
R&D Research and development 
RAP Reporting and Anal ysis Plan
RAS Renin-Angiotensin S ystem
RBC Red blood cells
rhACE2 Recombinant human angiotensin converting enzyme ty pe 2
RNA Ribonucleic acid
SAE Serious adverse event(s)
SaO2 Oxygen saturations
SGOT Serum glutami c-oxaloacetic transaminase
SGPT Serum glutamic p yruvic transaminase
SOA Schedule of Activities 
SOP Standard Operating Procedure
SRM Study Reference Manual
SUSAR Suspected, Unexpected, Serious Adverse drug Reaction
t½ Terminal phase half -life
tlast Time of last quantifiable concentration
tmax Time of occurrence of Cmax
ULN Upper limit of normal
VD Volume of distribution
WHO World Health Organization
WOCBP Women of Childbearing Potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
NONE WinNonlin 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
5012.2. Appendix2: Clinical Laboratory  Tests
The tests detailed in Table 1will be performed b y the central labo ratory. 
If a local sample is required, it is important that the sample for central analysis is 
obtained at the same time.
Protocol-specific requirements for inclusion or exclusion of participants are 
detailed in Section 6of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by the investigator or required by  local regulations.
Table 1Protocol -Required Safety  Laboratory  Assessments
Labor atory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Clinical 
Chemistry1BUN Potassium Aspartate 
Aminotransferase
(AST)/ Serum Glutamic -
Oxaloacetic 
Transaminase (SGOT)Total and direct bilirubin
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum Glutamic -
Pyruvic Transaminase 
(SGPT)Total Protein
Glucose Calcium Alkaline phosphata se International normalized 
ratio (INR)
Activated Prothrombin 
time (PT)
aPTT
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, bilirubin, Microscopic examination 
(only if blood or protein is abnormal)
Other 
Screening 
TestsFollicl e-stimulating hormone and estradiol (as needed in women of non -
childbearing potential only)
Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)2 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
51Labor atory 
AssessmentsParameters
Serology (HIV antibody, hepatitis B surface antigen [HBsAg], hepatitis C 
RNA and hepatitis C virus antibody)
NOTES :
1. Details of liver chemistry stopping criteria and required actions and follow -up assessments after liver stopping or 
monitoring event are given in Section 8.1and Appendix 7 . All events of ALT 3 × upper limit of normal (ULN) and 
bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) >1.5, if INR 
measured , which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis).
2. Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
5212.3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochur e, and other 
relevant documents ( e.g., advertisements) must be submitted to an I RB/IEC by  
the investigator and reviewed and approved b y the IRB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implemen tation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently  in accordance with the requirements, policies, 
and procedures established by  the IRB/IEC
Notifying the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of t he study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigators and sub -investigato rs will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participan t or his/her legally  authorized representative and answer all 
questions regarding the study .  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
53Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability  and Accountability  Act (HIPAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include astatement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study . 
A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by the sponsor in accordance with local data protection law. The level of 
disclosure must also be explained to the pa rticipant. 
The participant must be informed that his/her medical records may  be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appointed 
by the sponsor, b y appropriate IRB/IEC members, and by  inspectors from 
regulatory  authorities.
Publication Policy
The results of this study  may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to prot ect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generally support publication of multicenter studies only  in their entiret y and not 
as individual site data. In this case, a coordinating investigator will be 
designated b y mutual agreement.
Authorship will be determined by  mutual agreement and in line with 
International Committee of Medical Journal Editors authorship requirements. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
54Dissemination of Clinical Study  Data
This study  will be registered and stud y information from this protocol will be 
posted on publicly  available clinical trial registers before enrolment of study  
participants begins.
The results summary  of this study  will be posted to the GSK Clinical Study  
Register and other publicly  available clinical trialregisters within 8 months of the 
primary study completion date.
A manuscript reporting the study  results will be submitted to a peer reviewed 
journal within 18 months of the last participant’s last visit. 
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (eg, labor atory 
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b y physically or electronically signing the CRF. 
The investigator must maintain accurate documentation (source data) that 
supports the information entere d in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this stud y 
including qualit y checking of the data. 
Study monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  andrights of participants 
are being protected; and that the study is being conducted in accordance with the 
currently approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including sig ned ICF, pertaining to the conduct of this 
study must be retained by the investigator for 25years after study  completion 
unless local regulations or institutional policies require a longer retention period. 
No records may  be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another location or 
party without written notification to the sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
55Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, depending on the study . Also, current 
medical records must be available.
Study and Site Closure
GSK or its designee reserves the right to close the study site or terminate the study  at any 
time for an y reason at the sole discretion of GSK. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site by the sponsor or investigator may  include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participan ts bythe investigator
Discontinuation of further study  treatment development 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
5612.4. Appendix 4: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrenc e in a clinical study  participant, temporally  
associated with the use of a studytreatment, whether or not considered related to the 
study treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), symptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underlying disease).
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the star t of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
57convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurr ence that, at any dose:
a.Results in death
b.Is life-threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are AE. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary , the AE 
should be considered serious.
Hospitalization for elective treatment of a pre- existing condition that did not wo rsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of re latively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
everyday life functions but do not constitute a substantial disruption .
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may  
jeopardize the participant or may require medical or surgical intervention to prevent  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
58one of the other outcomes listed in the above definition. These events should usually  
be considered serious.
Examples of su ch events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrhythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
Recording A E and SA E
AE and SAE Recording
When an AE/SAE oc curs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to GSKin lieu of completion of the GSK /AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y GSK. In this case, a ll participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK.
The investigator will attempt to establish a diagnosis of the event based on signs,  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
59symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
everyday activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be asse ssed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationsh ip between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The inves tigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be co nsidered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator mustdocument in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK. However, it is very 
important that the investigator al ways make an assessment of causality for 
every event before the initial transmission of the SAE data to GSK.
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
60Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evalu ations as medically  indicated or as requested by  GSK to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide GSK with a cop y of any post-mortem 
findings including histopathology
New or updated information will b e recorded in the originally completed CRF.
The investigator will submit any  updated SAE data to GSK within 24 hours of 
receipt of the information.
Reporting of SA E to GSK
SAE Reporting to GSK via Electronic Data Collection Tool
The primary  mechanism fo r reporting SAE to GSK will be the electronic data 
collection tool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper SAE data collection tool (see next section).
The site will enter the SAE data into the elec tronic system as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off-line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE f rom a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor/SAE coordinator by  telephone.
Contacts for SAE reporting can be found in SRM. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
6112.5. Appendix5: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below)
Women in the following categories are not considered WOCBP
1.Premenarchal
2. Premenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history  interview.
3. Postmenopausal female
A postmenopausal state is defined as no menses for 12 mon ths without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Male participants
No specific contraception is required of males as the likelihood of study  drug dist ribution
in semen is low.
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in 
Table 2from screening up to 3days following treatment with study  drug. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
62Table 2 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulation
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulat ionb
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulation
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlus ion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used. )
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability o f sexual abstinence needs to be evaluated in relation to the duration of the study and 
the preferred and usual lifestyle of the participant.)
NOTES: 
a. Typical use failure rates may differ from those when used consistently and correctly. Use should be cons istent 
with local regulations regarding the use of contraceptive methods for participants inclinical studies. 
Pregnancy  Testing
WOCBP should only  be included after a negative highl y sensitive urine or serum
pregnancy test 
Additional pregnancy testing should be performed as specified in the SoA during the 
treatment period .
Pregnancy  testing will be performed when pregnancy  is otherwise suspected  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
63Pregnancy  testing, with a high sensitivity  test will be performed using the test kit in 
accordance with instructions provided in its package insert 
Collection of Pregnancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy  information on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to GSK within 
24 hours of learning of a participant's pregnancy . 
Participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to b e an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study pregnancy  which is considered 
reasonabl y related to the study  treatment by  the investigator, will be reported to GSK 
as described in Section 12.4. While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting. 
Any female participant who become s pregnant while participating will be withdrawn 
from the study . 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
6412.6. Appendix6: Genetics
There are no reported genetic mutations in ACE2 that have been associated with the 
development of PAH. However, genetic studies of a common insertion/deletion (I /D) 
polymorphism within the ACEgene appea rs to explain much of the variance observed in 
ACE enzy me expression levels, with the D allele conferring higher ACE and Ang II 
levels in tissue and serum (Marshall, 2002).  Numerous studies report genetic mutations
in ACE and association with various forms of pulmonary  hypertension. For example, in 
male subjects, but not in the female subjects, the ACE DD genot ype was negativel y 
associated with electrocardiographic evidence of right ventricular hy pertrophy (van 
Suylen,1999), and pulmonary  hypertension evoked by  exercise challenge in patients with 
Chronic Obstructive Pulmonary  Disease (COPD) ( Kanazawa ,2000) plus others.
USE/ANALYSIS O F DNA
Genetic variation may  impact a participant’s response to therap y, susceptibility , 
severity and progression of disease. Variable response to therap y may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology ; and/or molecular 
subtype of the disease being treated. Therefore, where local regulations and I RB/IEC 
allow, a blood sample will be collected for DNA analy sis
DNA samples maybe used for research relate d to [GSK2586881 ] or [PAH] and 
related diseases. They  may also be used to develop tests/assay s including diagnostic 
tests) related to GSK2586881 and PAHand related diseases. Genetic research may  
consist of the anal ysis of the entire genome.
DNA samples m ay be analyzed if it is hy pothesized that this may  help further 
understanding of the clinical data.  Analysis could include, but not be limited to, 
evaluation of the impact of I /D polymorphisms in the Angiotensin Converting 
Enzyme (ACE) gene on RAS peptide s, and responses to GSK2586881 
administration.
The samples may  be analyzed as part of a multi- study assessment of genetic factors 
involved in the response to GSK2586881 or study treatments of this class. The 
results of genetic anal yses may be reported in t he clinical study  report or in a 
separate study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained while research on GSK2586881 (or study treatments of 
this class) or PAH continues but no longer than 15 years or other period as per local 
requirements. 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
6512.7. Appendix 7: Liver Safety : Required A ctions and Follow -up 
Assessments
There are nocriteria for study  discontinuation as this is a single dose study ;howeverif 
any of the criteria for liver events (as described in the table below) are met, then the 
monitoring and follow -up assessments are required as described.
Phase II liver chemistry increased monitoring criteria have been designed to assure 
participant saf ety and evaluate liver event etiology  
Phase II liver chemistry additional monitoring criteria and required follow up 
assessments 
Liver Chemistry Additional Monitoring Criteria 
ALT- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsenin g) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Report the event to GSK within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver chemistry event follow up 
assessments 
Monitor the participant until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
MONITORING:
For bilirubin or INR criteri a:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform Viral hepatitis serology4
Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend
Obtain blood sample for 
pharmacokinetic (PK) analysis (with in 
24 hours) after last dose
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
66liver event follow up assessments within  24 hrs
Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A speci alist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-72 
hrs 
Monitor participants weekly until liver 
chemistries resolve, stabilize or return to within 
baselinedifferential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on t he liver event 
alcohol intake case report form (CRF) 
page 
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG) or gamma globulins.
Serum acetaminophen adduct high 
performance liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver 
injury in participants with definite or 
likely acetaminophen use in the 
preceding week (James, 2009). Liver 
imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
pages.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, recor d presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indic ate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A Ig M antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM); 
Hepatitis C RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, 
obtain heterophile antibody or monospot testing);  Hepat itis E IgM antibody  2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
67Phase II liver chemistry increased monitoring criteria 
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the GSK medical monitor within 24 hours of 
learning of the abnormality to discuss participant 
safety. 
Participant must return weekly for repeat liver 
chemistries (ALT, AS T, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time participant meets the liver chemistry 
stopping criteria, proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Kanazawa H, Okamoto T, Hirata K, Yoshikawa J.  Deletion Poly morphisms in the 
Angiotensin Converting Enzy me Gene Are Associated with Pulmonary  Hypertension 
Evoked b y Exercise Challenge in Patients with Chronic Obstructive Pulmonary  Disease. 
American Journal of Respiratory  and Criticial Care Medicine. 2000; 162: 1235-1238
Marshall RP, Webb S, Bellingan GJ et al. Angiotensin Converting Enz yme 
Insertion/Deletion Poly morphism I s Associated with Susceptibility  and Outcome in 
Acute Respiratory  Distress Sy ndrome. American Journal of Respiratory and Critical Care 
Medicine. 2002; 166: 646 -650
van Suylen RJ,  Wouters EF, Pennings HJ et al. The DD Genot ype of the Angiotensin 
Converting Enzy me Gene Is Negatively  Associated with Right Ventricular Hy pertrophy  
In Male Patients with Chronic Obstructive Pulmonary  Disease. American Journal of 
Respiratory  and Critical Care Medicine. 1999; 156: 1791 -1795 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
6812.8. Appendix 8: Protocol A mendment His tory
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC).
Amendment 3 01-Dec-2017
Overall Rationale for the Amendment
This is a substantial amendment to enable characterisation o f the response at a 
lower starting level of 0.1mg/kg GSK2586881.
Section # and 
NameDescription of Change Brief Rationale
Throughout Top (maximum) dose reduced from 
1.2mg/kg to 0.8mg/kg.1.2mg/kg dose removed to 
enable investigation of a 
0.1mg/kg group wi thout 
increasing the size of the study.
1. Synopsis
and
7.2 Dose 
ModificationPlanned doses changed from 0.2, 0.4, 0.8 
and 1.2mg/kg to 0.1, 0.2, 0.4 and 
0.8mg/kg.To enable characterisation of 
the dose response at 0.1mg/kg .
1. Synopsis Study design sch ematic. Changed to reflect new planned 
dose cohorts.
1. Synopsis
and
5.2 Number of 
Participants Additional participants can be recruited 
into a cohort prior to completion of all dose 
escalation.Changed to allow t he total 
number of participants recrui ted 
per cohort tobe determined 
through an ongoing review of 
the safety, tolerability, PK and 
PD data prior to dose escalation . 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
69Amendment 2 07-Nov-2017
Overall Rationale for the Amendment:
This is a non- substantial amendment to clarify  the target popul ation to be enrolled, the 
changes to the inclusion and exclusion criteria are listed in the table below.  I n addition, 
an upper limit for the 6MW was added, the evaluable population was changed, and the 
proposed linear regression anal ysis was expanded. 
Section # and 
NameDescription of Change Brief Rationale
Throughout Transpulmonary RAS biomarkers was 
changed to pulmonary wedge RAS .Transpul monar y is the position 
the sample is taken however a 
more appropriate way of 
describing this sample is 
pulmonary wedge RAS .
2. Schedule of 
ActivitiesNotes were added for genetic consent and 
genetic sampleNotes were added to ensure the 
timing and consent proc ess are 
clear for the genetic sample.
6.1 Inclusion 
CriteriaA maximum distance of 450 meters was 
added for the Six minute walk (6MW) 
distance .To confine the participant 
population to WHO functional 
class I, II, and III subjects .
6.2 Exclusion 
CriteriaAdded renin inhibitors as restricted 
concomitant medication .Renin inhibitors may potentially 
reduce Ang I and subsequently 
Ang II levels which is the target 
of ACE2 so by e xcluding them 
patients have a better chance of 
having elevated Ang II .
10.2 Popul ation 
for Analysis Evaluable population was changed from 
participants that completed day 7 and 14 
follow ups to include partic ipants that 
complete day 1 .To ensure partic ipants lost to 
follow up will still be included in 
the ev aluable population .
10.3.1 and 10.3.3 
Statistical 
Analysis Proposed linear regression analysis 
expanded to include other primary 
endpoin ts CO and mPAP if data permit 
(Section 10.3.1 and Section 10.3.3).Expanded to assess additional 
hemodynamic measurements 
(primary endpoints) in relation to 
dose of GSK2586881 2019N405280_00
2016N290015_04 CONFIDENTIA L
206246
70Amendment 1 03-May-2017
Overall Rationale for the Amendment: The protocol was amended to include the risk 
of exposure to ionizing radiation that was previously  omitted and update information on 
participant rescreening numbe rs. 
Section # and 
NameDescription of Change Brief Rationale
3.3.1 Risk 
Assessment Risk of exposure to ionizing 
radiation was addedSome participants will be exposed to 
ionizing radiation as part of the right heart 
catheterization, therefore the risk wa s 
added. 
9.1.1 
HemodynamicsThe procedure of confirming the 
right heart catheter placement by 
chest X -ray or fluoroscopy was 
added.Procedure was added to ensure clear 
understanding. 
6.4 Screen 
FailuresRescreened participants should be 
assigned a new participant 
number.Due to a change in eCRF system 
rescreened participants will be assigned a 
new number. 
12.4 Appendix 
4Added SAE Reporting to GSK via 
Paper CRFMissing from original protocol  2019N405280_00